XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.

PHASE3CompletedINTERVENTIONAL

Enrollment

581

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Restless Legs Syndrome

Interventions

DRUG

XP13512 (GEn)

1200 mg XP13512, orally, once daily for 52 weeks

All Listed Sponsors

lead

XenoPort, Inc.

INDUSTRY

NCT00333359 - XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome. | Biotech Hunter | Biotech Hunter